Better Choice Company Appoints Renowned Expert in Rare and Undiagnosed Diseases, Dr. Paldeep S. Atwal, as its United States Special Healthcare Advisor
04 Mars 2025 - 4:00PM
Better Choice Company, Inc. (NYSE American: BTTR) (“Better Choice”
or the “Company”), a pet health and wellness company, today
announced the appointment of Dr. Paldeep S. Atwal as its
United States Special Healthcare Advisor.
Renowned for his expertise in rare and
undiagnosed diseases, Dr. Atwal has dedicated his career to
advancing the field of genomic medicine through cutting-edge
diagnostics, research, and patient care. Dr. Atwal is a
board-certified clinical and medical biochemical geneticist and the
founder of Atwal Clinic for Genomic & Personalized Medicine, a
premier private genetics clinic in Palm Beach, FL. Previously, he
served as Medical Director of Genetic Services at Everly Health
Solutions (formerly PWNHealth), a leading virtual healthcare
company, and as Medical Director for the Individualized Medicine
Clinic at Mayo Clinic in Florida, where he played a pivotal role in
advancing precision medicine initiatives.
"As we near the closing of our acquisition of
SRx Health, it is critical we continue to build our team with
healthcare professionals and experts such as Dr. Atwal," said
Michael Young, Chairman of Better Choice. "Dr. Atwal’s appointment
will be key in accelerating the our growth, particularly in new
offerings, strategic healthcare partnerships, and aligning with the
evolving wellness and preventative health landscape. Dr. Atwal's
pioneering work in genomic medicine, combined with his vast
expertise in rare diseases and personalized care, will be
invaluable as we continue to innovate and expand our health and
wellness offerings. His strategic vision will be instrumental in
shaping our future initiatives and ensuring we lead the way in
delivering impactful health solutions that truly improve
lives."
As a recognized leader in genomic medicine, Dr.
Atwal is committed to advancing personalized, science-driven care,
with his pioneering contributions earning numerous prestigious
awards, including the ACMG Foundation/Genzyme Fellowship, and the
Neurobiology of Disease in Children Young Investigator Award. Dr.
Atwal earned his medical degree from the University of Glasgow and
trained in internal medicine at Glasgow Royal Infirmary with the
Royal College of Physicians. He also pursued a genetics fellowship
at Stanford University and a sub-specialty biochemical genetics
fellowship at Baylor College of Medicine, where he contributed to
the development of a clinical metabolomic profiling test.
About Better Choice Company
Inc. Better Choice Company Inc. is a rapidly growing pet
health and wellness company committed to leading the industry shift
toward pet products and services that help dogs and cats live
healthier, happier, and longer lives. We take an alternative,
nutrition-based approach to pet health relative to conventional dog
and cat food offerings and position our portfolio of brands to
benefit from the mainstream trends of growing pet humanization and
consumer focus on health and wellness. We have a demonstrated,
multi-decade track record of success selling trusted pet health and
wellness products and leverage our established digital footprint to
provide pet parents with the knowledge to make informed decisions
about their pet’s health. We sell the majority of our dog food, cat
food and treats under the Halo brand, which is focused,
respectively, on providing sustainably sourced kibble and canned
food derived from real whole meat, and minimally processed raw-diet
dog food and treats. For more information, please
visit https://www.betterchoicecompany.com.
Forward Looking StatementsThis
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
The words “believe,” “may,” “estimate,” “continue,” “anticipate,”
“intend,” “should,” “plan,” “could,” “target,” “potential,” “is
likely,” “will,” “expect” and similar expressions, as they relate
to us, are intended to identify forward-looking statements. The
Company has based these forward-looking statements largely on our
current expectations and projections about future events and
financial trends that we believe may affect our financial
condition, results of operations, business strategy and financial
needs. Some or all of the results anticipated by these
forward-looking statements may not be achieved. Further information
on the Company’s risk factors is contained in our filings with the
SEC. Any forward-looking statement made by us herein speaks only as
of the date on which it is made. Factors or events that could cause
our actual results to differ may emerge from time to time, and it
is not possible for us to predict all of them. The Company
undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future
developments or otherwise, except as may be required by law.
Company Contact:Better Choice Company, Inc.Kent
Cunningham, CEO
Investor Contact:KCSA Strategic
CommunicationsValter Pinto, Managing DirectorT:
212-896-1254Valter@KCSA.com
Better Choice (AMEX:BTTR)
Graphique Historique de l'Action
De Fév 2025 à Mar 2025
Better Choice (AMEX:BTTR)
Graphique Historique de l'Action
De Mar 2024 à Mar 2025